Lewes, DE -- (SBWIRE) -- 09/30/2015 -- Non-Hodgkin Lymphoma Treatment Pipeline Shows Below Average Innovation

The product pipeline for Non-Hodgkin Lymphoma (NHL) exhibits a lower degree of innovation than both the industry and oncology average, with just 28% of all pipeline products, or 33% of the pipeline for which there is a disclosed molecular target, categorized as first-in-class. This is in comparison to industry, breast cancer and lung cancer innovation rates of 43%, 57% and 59%, respectively, According to New Report.

The company's latest report states that while NHL, collectively, is the sixth to tenth most common cancer dependent on territory, each individual subtype is classified as an orphan disease. With significant differences in each subtype's genetic profile and current treatment, there is reduced scope for the development of a targeted therapy with cross-subtype activity.

This does not present NHL drug development as an attractive investment in comparison to other indications in oncology, particularly as survival durations across many NHL subtypes are relatively strong, and likely the reason for low first-in-class innovation levels.

According to Senior Analyst for Publisher says that innovation is present to varying degrees across the majority of molecular target families and development stages for NHL therapeutics, rather than localized to a particular subset of therapies.

Senior Analyst says: "There is a considerable range of clinical potential across treatments with first-in-class status, particularly those restricted to the early-stage NHL pipeline. Some targets, such as spleen tyrosine kinase, boast plenty of supporting scientific and clinical evidence, while others have shown mixed results in Preclinical studies and lack clarity on their role in disease pathophysiology."

The report also notes that despite the difficulty of several targeted NHL therapies in achieving improved efficacy rates, the development of such treatments remains of key interest across NHL.

Senior Analyst continues: "It is hoped that one of these many targeted therapy pipeline products will replicate the success observed with rituximab, which significantly altered the NHL treatment landscape following its approval.

"Clear gaps in the treatment algorithm include maintenance therapies to prolong initial or subsequent durations of remission, and improved therapies for relapsed patients, particularly those with a second or subsequent relapse," the analyst concludes.

Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma report provides analysis of the Non-Hodgkin Lymphoma (NHL) treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the NHL therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher's team of industry experts.

For further information on this report, please visit- http://www.marketresearchreports.com/gbi-research/frontier-pharma-innovative-licensing-opportunities-non-hodgkin-lymphoma

Related Reports:

1st - Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth – See more at - http://www.marketresearchreports.com/gbi-research/type-2-diabetes-mellitus-therapeutics-major-developed-markets-2021-strong-pipeline-and

2nd - Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation - See more at - http://www.marketresearchreports.com/gbi-research/frontier-pharma-versatile-innovation-oncology-identifying-and-commercializing-versatile

3rd - Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline - See morea at - http://www.marketresearchreports.com/gbi-research/anti-hypertensive-therapeutics-asia-pacific-markets-2021-increasing-prevalence

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions